191 related articles for article (PubMed ID: 9378499)
21. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides.
Leifer CA; Verthelyi D; Klinman DM
J Immunother; 2003; 26(4):313-9. PubMed ID: 12843793
[TBL] [Abstract][Full Text] [Related]
23. CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll.
Chelvarajan RL; Raithatha R; Venkataraman C; Kaul R; Han SS; Robertson DA; Bondada S
Eur J Immunol; 1999 Sep; 29(9):2808-18. PubMed ID: 10508255
[TBL] [Abstract][Full Text] [Related]
24. A mutant of the WEHI-231 B lymphocyte line that is resistant to phorbol esters is still sensitive to antigen receptor-mediated growth inhibition.
Haggerty HG; Monroe JG
Cell Immunol; 1994 Mar; 154(1):166-80. PubMed ID: 8118885
[TBL] [Abstract][Full Text] [Related]
25. Anti-proliferative effects of phosphodiester oligodeoxynucleotides.
Bjersing JL; Tarkowski A; Collins LV
Immunobiology; 2004; 209(8):637-45. PubMed ID: 15638132
[TBL] [Abstract][Full Text] [Related]
26. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
Castro JE; Prada CE; Aguillon RA; Kitada S; Fukuda T; Motta M; Wu C; Dicker F; Sun G; Wang JY; Carson DA; Reed JC; Kipps TJ
Leukemia; 2006 Apr; 20(4):680-8. PubMed ID: 16498393
[TBL] [Abstract][Full Text] [Related]
27. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
28. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death.
Sohn WJ; Lee KW; Choi SY; Chung E; Lee Y; Kim TY; Lee SK; Choe YK; Lee JH; Kim DS; Kwon HJ
Mol Immunol; 2006 Mar; 43(8):1163-71. PubMed ID: 16122803
[TBL] [Abstract][Full Text] [Related]
29. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T; Peschel C
Leuk Lymphoma; 2001 Jul; 42(3):301-7. PubMed ID: 11699394
[TBL] [Abstract][Full Text] [Related]
30. CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways.
Qi XF; Zheng L; Kim CS; Lee KJ; Kim DH; Cai DQ; Qin JW; Yu YH; Wu Z; Kim SK
Mol Immunol; 2013 Jul; 54(3-4):327-37. PubMed ID: 23357786
[TBL] [Abstract][Full Text] [Related]
31. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses.
Jakob T; Walker PS; Krieg AM; von Stebut E; Udey MC; Vogel JC
Int Arch Allergy Immunol; 1999; 118(2-4):457-61. PubMed ID: 10224474
[TBL] [Abstract][Full Text] [Related]
32. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide.
Manzel L; Macfarlane DE
Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):459-64. PubMed ID: 10555153
[TBL] [Abstract][Full Text] [Related]
33. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo.
Tan Y; Li S; Pitt BR; Huang L
Hum Gene Ther; 1999 Sep; 10(13):2153-61. PubMed ID: 10498247
[TBL] [Abstract][Full Text] [Related]
34. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.
Britigan BE; Lewis TS; Waldschmidt M; McCormick ML; Krieg AM
J Immunol; 2001 Sep; 167(5):2921-8. PubMed ID: 11509640
[TBL] [Abstract][Full Text] [Related]
35. CpG inhibits IgE class switch recombination through suppression of NF kappa B activity, but not through Id2 or Bcl6.
Kusunoki T; Sugai M; Gonda H; Nambu Y; Nagata-Nakajima N; Katakai T; Kusunoki M; Sakamoto A; Tokuhisa T; Nakahata T; Yokota Y; Shimizu A
Biochem Biophys Res Commun; 2005 Mar; 328(2):499-506. PubMed ID: 15694375
[TBL] [Abstract][Full Text] [Related]
36. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
37. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
38. Lymphoma models for B cell activation and tolerance. V. Anti-Ig mediated growth inhibition is reversed by phorbol myristate acetate but does not involve changes in cytosolic free calcium.
Scott DW; Livnat D; Whitin J; Dillon SB; Snyderman R; Pennell CA
J Mol Cell Immunol; 1987; 3(2):109-20. PubMed ID: 3509921
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA.
Kim D; Rhee JW; Kwon S; Sohn WJ; Lee Y; Kim DW; Kim DS; Kwon HJ
Biochem Biophys Res Commun; 2009 Feb; 379(2):362-7. PubMed ID: 19103173
[TBL] [Abstract][Full Text] [Related]
40. CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.
Nørgaard NN; Holien T; Jönsson S; Hella H; Espevik T; Sundan A; Standal T
J Immunol; 2010 Sep; 185(6):3131-9. PubMed ID: 20702733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
